Humira (adalimumab) was the best-selling drug in the world for nearly a decade, generating over $21 billion in annual U.S. sales at its peak. The arrival of biosimilar Humira alternatives has fundamentally changed the cost landscape for millions of patients with conditions like rheumatoid arthritis, Crohn’s disease, and psoriasis. With multiple FDA-approved biosimilars now on the market, competition has driven prices down by as much as 85 percent, creating the largest biosimilar savings opportunity in U.S. history.
What Is Humira and Who Takes It?
Humira is a monoclonal antibody that targets tumor necrosis factor alpha (TNF-alpha), a protein that drives inflammation throughout the body. The FDA first approved Humira in December 2002 for rheumatoid arthritis, and AbbVie subsequently obtained approvals for a total of 12 indications, including psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.
At its peak, Humira was prescribed to over 400,000 patients in the United States. The drug’s list price climbed steadily over the years, reaching approximately $7,000 per month before biosimilar competition began. This pricing trajectory made Humira a symbol of the broader debate around biologic drug affordability and the role of drug patents in sustaining high prices.
The Patent Cliff: How Biosimilar Competition Arrived
AbbVie built an extensive patent portfolio around Humira, at one point holding over 100 patents covering the drug’s formulation, manufacturing process, and various uses. This “patent thicket” strategy delayed biosimilar entry well beyond the expiration of Humira’s core composition-of-matter patent in 2016.
Through a series of patent settlements with biosimilar manufacturers, AbbVie agreed to license entry beginning in January 2023 for the U.S. market. This date became the starting point for biosimilar Humira competition in the United States, years after biosimilar adalimumab products had already launched in Europe and other markets.
FDA-Approved Adalimumab Biosimilars
The FDA has approved multiple biosimilar versions of adalimumab, making this one of the most competitive biosimilar categories in the United States. Key approved products include:
Hadlima (adalimumab-bwwd), manufactured by Samsung Bioepis and marketed by Organon, received FDA approval in July 2019 and launched in the U.S. market in 2023. Hyrimoz (adalimumab-adaz), developed by Sandoz, was approved in October 2018. Cyltezo (adalimumab-adbm), from Boehringer Ingelheim, was the first adalimumab biosimilar to receive an interchangeability designation from the FDA in October 2021, a landmark regulatory achievement.
Amjevita (adalimumab-atto), manufactured by Amgen, was actually the first adalimumab biosimilar approved by the FDA back in September 2016 but did not launch until 2023 due to patent settlement terms. Yusimry (adalimumab-aqvh), from Coherus BioSciences, and Idacio (adalimumab-aacf), from Fresenius Kabi, are among the additional approved options available to patients and prescribers.
Cost Savings: What Patients Are Actually Seeing
The biosimilar Humira market has demonstrated the power of competition to drive down biologic drug prices. Initial biosimilar launches in January 2023 offered discounts of 5 to 15 percent below Humira’s list price, a modest start that disappointed some observers. However, as more biosimilars entered the market throughout 2023 and 2024, competition intensified significantly.
By late 2024, some adalimumab biosimilars were available at discounts of 80 to 85 percent below Humira’s pre-competition list price. AbbVie itself responded by launching an unbranded version of Humira at a reduced price, adding further competitive pressure. For patients paying out of pocket, this translates to potential savings of $5,000 to $6,000 per month compared to the original Humira price.
Actual patient savings depend heavily on insurance coverage, formulary placement, and copay structures. Many payers have moved biosimilar adalimumab products to preferred formulary positions, requiring patients to try a biosimilar before the reference product will be covered. Tools like GoodRx can help patients compare prices across biosimilar options and pharmacies.
Safety and Switching Data
Clinical trials for each approved adalimumab biosimilar demonstrated no clinically meaningful differences from Humira in safety, efficacy, or immunogenicity. Phase III studies typically enrolled several hundred patients with rheumatoid arthritis or plaque psoriasis and compared clinical response rates, adverse event profiles, and anti-drug antibody development between the biosimilar and reference product.
Switching studies have provided additional reassurance. Cyltezo’s interchangeability trial, for example, demonstrated that patients who switched between Cyltezo and Humira multiple times experienced no increased risk of adverse events or diminished efficacy compared to patients who remained on Humira continuously. Real-world post-marketing data from European markets, where biosimilar adalimumab has been available since 2018, further support the safety of switching.
Major rheumatology, gastroenterology, and dermatology organizations have issued position statements supporting the use of biosimilar adalimumab, including for patients currently stable on Humira. For more on biosimilar safety standards, see our guide on what biosimilars are.
Interchangeability: What It Means for Your Prescription
Cyltezo’s interchangeability designation means that, in states where pharmacy law permits, a pharmacist can substitute Cyltezo for Humira without requiring a new prescription from the physician. This mirrors the automatic substitution process that patients experience with generic vs brand name drugs.
Other adalimumab biosimilars that lack interchangeability status can still be prescribed by physicians, but the switch must originate from the prescriber rather than the pharmacist. In practice, many payers are achieving biosimilar adoption through formulary management rather than relying on pharmacy-level substitution, by placing biosimilars on preferred tiers and requiring prior authorization for the reference product.
How to Switch from Humira to a Biosimilar
If you are currently taking Humira and want to explore a biosimilar alternative, start by talking to your prescribing physician. They can evaluate whether a switch is appropriate based on your specific medical history, disease stability, and insurance coverage. Most patients who are stable on Humira can transition to a biosimilar without any adjustment to their treatment plan.
Contact your insurance provider or pharmacy benefit manager (PBM) to understand which adalimumab products are covered under your plan and at what cost-sharing level. Some plans may require you to switch to a biosimilar, while others may offer financial incentives for voluntary switching. Your specialty pharmacy can also provide guidance on transitioning between products and managing any differences in injection devices or administration procedures.
Frequently Asked Questions
Are Humira biosimilars as effective as the original?
Yes. Every FDA-approved adalimumab biosimilar has demonstrated equivalent efficacy to Humira in rigorous clinical trials. Response rates for conditions including rheumatoid arthritis and psoriasis have been statistically indistinguishable between biosimilars and the reference product. Years of real-world data from Europe confirm these findings.
Will my insurance cover a biosimilar Humira?
Most insurance plans now cover at least one adalimumab biosimilar, and many have placed biosimilars on preferred formulary tiers with lower cost-sharing than Humira. Some plans require biosimilar use as a first-line treatment before Humira will be covered. Check with your insurance provider for specific coverage details.
Can I switch back to Humira if the biosimilar doesn’t work for me?
Yes, though the clinical data suggest this scenario is uncommon. If you experience any issues after switching to a biosimilar, your physician can adjust your treatment plan, including switching to a different biosimilar or returning to the reference product. The key is to communicate any changes in symptoms or side effects to your healthcare team promptly.
How do adalimumab biosimilars differ from each other?
While all approved adalimumab biosimilars contain the same active ingredient and have demonstrated biosimilarity to Humira, they may differ in formulation details, citrate content (which can affect injection site pain), injection device design, and pricing. Your physician and pharmacist can help you identify which specific product best suits your needs and preferences. Understanding the biosimilar vs generic distinction can also be helpful.
The Future of Adalimumab Competition
The adalimumab biosimilar market represents a template for how biosimilar competition can transform access to expensive biologic therapies. As additional biosimilars continue to launch and compete, prices are expected to stabilize at levels dramatically below historical Humira pricing. This market evolution has implications not only for patients taking adalimumab but for the broader trajectory of healthcare costs in the biologic drug category. Staying informed about healthcare policy developments can help you anticipate how these competitive dynamics will affect your access and costs going forward.